AI-Driven Drug Pricing Strategy and Gross-to-Net Optimization

AI-Driven Drug Pricing Strategy and Gross-to-Net Optimization In this episode of Center of Excellence – Pharma 4.0, we explore how artificial intelligence is revolutionizing one of the most complex and financially critical areas in the pharmaceutical industry: drug pricing strategy and Gross-to-Net (GTN) optimization. The discussion begins by unpacking the intricate structure of the GTN “bubble”—the widening gap between a drug’s list price and the actual net revenue realized by manufacturers. From commercial payer rebates and government mandates to distribution fees and patient support programs, we break down how value leakage occurs and why traditional spreadsheet-based approaches are no longer sufficient. We then trace the evolution of AI in this space. The first wave, driven by Generative AI, focused on improving operational efficiency—automating market access dossiers, summarizing payer policies, and accelerating rebate documentation. While impactful, these tools remained limited to text generation and lacked the ability to simulate real financial outcomes. The episode dives deeper into the transformative shift toward Agentic AI, where autonomous systems actively model GTN dynamics in real time. These advanced platforms ingest live data—from payer coverage and pricing benchmarks to channel mix—and run complex simulations within minutes. This enables finance leaders to proactively evaluate pricing decisions, mitigate risks, and optimize net revenue before contracts are finalized. We also examine how AI is helping pharma organizations navigate mounting external pressures, including regulatory changes such as the Inflation Reduction Act, global pricing constraints, and the rise of biosimilar competition. By continuously monitoring and simulating these variables, AI empowers companies to protect margins and maintain strategic agility in a rapidly evolving market. Finally, the episode highlights measurable outcomes and ROI, showcasing how even small improvements in GTN yield can translate into significant financial gains at scale. We conclude with a practical roadmap for implementation—guiding organizations from data consolidation and generative enablement to fully integrated, continuously governed AI-driven pricing ecosystems. This episode is essential listening for pharma executives, CFOs, and digital transformation leaders seeking to move beyond reactive pricing strategies and embrace AI-powered revenue intelligence as a competitive advantage. Resources: Book Series: Center of Excellence – Pharma 4.0 https://www.amazon.com/dp/B0F1DX4XXB Udemy Course: Smart Manufacturing in Pharma https://www.udemy.com/course/smart-manufacturing-in-pharma/ Subscribe to our YouTube channel https://www.youtube.com/@COE-PHARMA4.0 Website: https://respa.com and follow the Podcast https://pharma4coe.podbean.com for more insights on the future of Pharma! #PharmaFinance #RevenueOptimization #DigitalTransformation #LifeSciences #MarketAccess #AITransformation #PharmaStrategy #CFOInsights #HealthcareAI